

CORRECTION

OPEN



Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia

Thi Thanh Vu, Friedrich Stölzel, Kristy W. Wang, Christoph Röllig, Melinda L. Tursky ID, Timothy J. Molloy ID and David D. Ma

© The Author(s) 2025

Leukemia (2025) 39:3059; <https://doi.org/10.1038/s41375-025-02788-z>

Correction to: *Leukemia* <https://doi.org/10.1038/s41375-020-01095-z>, published online 01 December 2020

Following the publication of this article, an overlap was noted in two of the histological images in Figure 8b, labelled "Nutlin-3a + Cytarabine". The tissue samples used are now >7 years old and unfortunately are unable to be located. As this figure is an ancillary figure, that does not alter the key findings of the paper, the decision was taken to remove the figure and legend. The sentence referring to this figure in the final paragraph of the Results section has also been removed: "Improved survival was consistent with significantly lower human CD45 positive (hCD45+) leukemic cell infiltrate in the spleen of miR-10a inhibited vs control animals collected after 7 days of treatment (all except vehicle $p < 0.05$; Fig. 8b). The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025